Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACE | P12821 | 2/20 | 0.51 |
| ▸ | HPGDS | O60760 | 3/20 | 0.49 |
| ▸ | MME | P08473 | 1/20 | 0.49 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.47 |
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.46 |
| ▸ | PSMB5 | P28074 | 1/20 | 0.46 |
| ▸ | MEP1B | Q16820 | 2/20 | 0.46 |
| ▸ | FCER2 | P06734 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20362252 | 1.00 | ACE (0.51) | ACEHPGDSMMETRPV1SLC7A5 | |
| SCHEMBL8843830 | 0.92 | EPHX1 (0.51) | HPGDSSLC7A5PSMB5MEP1B | |
| SCHEMBL9706212 | 0.92 | EPHX1 (0.51) | HPGDSSLC7A5PSMB5MEP1B | |
| SCHEMBL11346818 | 0.88 | MME (0.58) | ACEMMESLC7A5PSMB5 | |
| SCHEMBL6065430 | 0.88 | MME (0.58) | ACEMMESLC7A5PSMB5 | |
| SCHEMBL121371 | 0.88 | MME (0.58) | ACEMMESLC7A5PSMB5 | |
| SCHEMBL6716497 | 0.88 | MME (0.58) | ACEMMESLC7A5PSMB5 | |
| SCHEMBL121370 | 0.88 | MME (0.58) | ACEMMESLC7A5PSMB5 | |
| SCHEMBL30882625 | 0.85 | OPRK1 (0.50) | ACEMMETRPV1 | |
| Hydrochloric Acid SCHEMBL30882508 | 0.84 | OPRK1 (0.49) | ACEMMETRPV1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11484525-B2 | Mu opioid receptor modulators | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2022-11-01 | — | — | US | disclosed |
| EP-3319444-B1 | MU OPIOID RECEPTOR MODULATORS | UNIV CALIFORNIA (US) | 2022-03-09 | — | — | EP | disclosed |
| US-20210052548-A1 | MU OPIOID RECEPTOR MODULATORS | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 2021-02-25 | — | — | US | disclosed |
| US-20210052548-A1 | MU OPIOID RECEPTOR MODULATORS | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 2021-02-25 | — | — | US | disclosed |
| US-10702498-B2 | MU opioid receptor modulators | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2020-07-07 | — | — | US | disclosed |
| US-10702498-B2 | MU opioid receptor modulators | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2020-07-07 | — | — | US | disclosed |
| US-20200109126-A1 | MU OPIOID RECEPTOR MODULATORS | UNIV CALIFORNIA (US) | 2020-04-09 | — | — | US | disclosed |
| US-20200109126-A1 | MU OPIOID RECEPTOR MODULATORS | UNIV CALIFORNIA (US) | 2020-04-09 | — | — | US | disclosed |
| EP-3565543-A1 | MU OPIOID RECEPTOR MODULATORS | The Regents of The University of California (US) | 2019-11-13 | — | — | EP | disclosed |
| US-20190076398-A1 | MU OPIOID RECEPTOR MODULATORS | Friedrich-Alexander-Universität Erlangen-Nürnberg (DE) | 2019-03-14 | — | — | US | disclosed |
| US-20190076398-A1 | MU OPIOID RECEPTOR MODULATORS | Friedrich-Alexander-Universität Erlangen-Nürnberg (DE) | 2019-03-14 | — | — | US | disclosed |
| WO-2018129393-A1 | MU OPIOID RECEPTOR MODULATORS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2018-07-12 | — | — | WO | disclosed |
| WO-2018129393-A1 | MU OPIOID RECEPTOR MODULATORS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2018-07-12 | — | — | WO | disclosed |
| WO-2017007695-A1 | MU OPIOID RECEPTOR MODULATORS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2017-01-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11484525-B2 | Mu opioid receptor modulators | OPRM1, OPRK1, OPRD1 | ACE 3421/4885HPGDS 1327/4885MME 570/4885 |
| US-10702498-B2 | MU opioid receptor modulators | OPRM1, OPRK1, OPRD1 | ACE 3421/4885HPGDS 1327/4885MME 570/4885 |
| US-20190076398-A1 | MU OPIOID RECEPTOR MODULATORS | OPRM1, OPRK1, OPRD1 | ACE 3421/4885HPGDS 1327/4885MME 570/4885 |
| US-20210052548-A1 | MU OPIOID RECEPTOR MODULATORS | OPRM1, OPRK1, OPRD1 | ACE 3421/4885HPGDS 1327/4885MME 570/4885 |
| US-20200109126-A1 | MU OPIOID RECEPTOR MODULATORS | OPRM1, OPRK1, OPRD1 | ACE 3421/4885HPGDS 1327/4885MME 570/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.